Piper Sandler Increases Masimo (NASDAQ:MASI) Price Target to $215.00

Masimo (NASDAQ:MASI) had its price objective lifted by stock analysts at Piper Sandler from $210.00 to $215.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the medical equipment provider’s stock. Piper Sandler’s price target indicates a potential upside of 15.47% from the stock’s current price.

Several other equities research analysts also recently issued reports on the company. Raymond James increased their target price on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a report on Wednesday. Wells Fargo & Company lifted their target price on Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $190.00 price target (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Masimo has a consensus rating of “Moderate Buy” and an average target price of $194.80.

Masimo Stock Down 2.2 %

Shares of NASDAQ MASI opened at $186.20 on Wednesday. The business’s fifty day moving average price is $172.95 and its 200-day moving average price is $153.10. Masimo has a one year low of $101.61 and a one year high of $192.62. The stock has a market capitalization of $9.97 billion, a PE ratio of 128.41 and a beta of 1.02. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11.

Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm had revenue of $600.70 million during the quarter, compared to analyst estimates of $593.35 million. On average, equities research analysts anticipate that Masimo will post 4.1 EPS for the current year.

Institutional Trading of Masimo

Institutional investors and hedge funds have recently modified their holdings of the business. Allspring Global Investments Holdings LLC increased its position in shares of Masimo by 5,340.9% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,394 shares of the medical equipment provider’s stock worth $319,000 after purchasing an additional 2,350 shares during the last quarter. State of Alaska Department of Revenue grew its stake in Masimo by 7.2% in the 3rd quarter. State of Alaska Department of Revenue now owns 5,139 shares of the medical equipment provider’s stock worth $685,000 after buying an additional 345 shares in the last quarter. SteelPeak Wealth LLC bought a new position in shares of Masimo in the 3rd quarter worth $570,000. Roubaix Capital LLC raised its position in shares of Masimo by 37.0% during the 3rd quarter. Roubaix Capital LLC now owns 34,041 shares of the medical equipment provider’s stock valued at $4,539,000 after buying an additional 9,202 shares in the last quarter. Finally, Malaga Cove Capital LLC bought a new stake in shares of Masimo during the 3rd quarter worth $401,000. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.